BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend)

BPC‑157, TB‑500, KPV, GHK‑Cu 80 mg (Klow Blend) is a multi‑peptide combination that brings together several research peptides with different biological activities. BPC‑157 (Body Protection Compound‑157) is a 15‑amino‑acid peptide studied in animal and laboratory research for its potential to support tissue repair, angiogenesis (new blood vessel formation), and modulation of inflammatory responses in muscle, tendon, ligament, nerve, and gastrointestinal tissues. TB‑500 is a synthetic fragment of thymosin beta‑4 associated in preclinical models with enhanced cell migration and tissue remodelling. KPV is a tripeptide (lysine‑proline‑valine) derived from alpha‑melanocyte‑stimulating hormone that has been explored for its anti‑inflammatory and immune‑modulating effects, particularly in gut and skin models. GHK‑Cu (copper peptide) is known in cosmetic and regenerative research for signalling pathways linked to collagen production, antioxidant defence, and skin repair. An 80 mg “Klow Blend” aims to combine these peptides’ complementary mechanisms, with the idea of supporting tissue healing, recovery, and skin regeneration more broadly than individual components alone.

Despite scientific interest, this peptide blend is not approved for therapeutic or cosmetic use by the U.S. Food and Drug Administration and remains a research compound. Most evidence for the individual peptides comes from in‑vitro or animal studies, and rigorous human clinical data on safety, efficacy, and appropriate dosing are limited or lacking. Products sold with such blends are typically labeled “for research use only,” meaning their purity and quality can vary widely and are not regulated to pharmaceutical standards. Some of the components, like BPC‑157 and TB‑500, are also prohibited in competitive sport by the World Anti‑Doping Agency due to potential performance‑enhancing use. Given these uncertainties and regulatory statuses, individuals should avoid self‑administration and consult qualified healthcare professionals when considering peptide research or treatments.